Adverum announces first patient dosed in OPTIC phase 1 trial of ADVM-022 gene therapy
Adverum Biotechnologies announced that the first patient was dosed in the OPTIC phase 1 trial evaluating ADVM-022 for patients with wet age-related macular degeneration. At least six leading retinal centers across the United States are expected to participate in the phase 1 trial. November 19, 2018